THC BioMed's Subsidiary Gets Approval from Health Canada to Produce Fresh Marijuana, Cannabis Oil and Cannabis Resin - Video News Alert on InvestmentPitch.com

Vancouver, British Columbia--(Newsfile Corp. - May 25, 2016) - Health Canada has granted authorization to THC BioMed Intl's (CSE: THC) (OTC Pink: THCBF) (FSE: TFHC) wholly-owned subsidiary, THC BioMed Ltd., to produce fresh marijuana, cannabis oil, and cannabis resin.

InvestmentPitch Media has produced a "video news alert" which provides a brief overview of the company. If this link is not enabled, please visit www.InvestmentPitch.com and enter "THC BioMed" in the search box.

If you cannot view the video above, please visit:
http://www.investmentpitch.com/video/0_u9kwoa0g/THC-BioMed-CSE-THC-gets-Canada-Health-authorization-for-production

THC BioMed will immediately begin development of a wide range of products including medical grade dried cannabis, CBD, THC oils and cannabis infused products for topical application. However, the company is awaiting approval by Health Canada, for a sale amendment to its license, prior to releasing the products for sale.

The company set another milestone, setting the foundation of another subsidiary, Seeds R Us, which is focused on establishing a national supply chain for cannabis genetics. The company is now carrying a diverse selection of seeds, imported from Holland, including high CBD and high THC producing strains, which are listed on the website www.THCBioMed.com, under the Seeds R Us tab. Both THC and CBD levels are shown, with profiling for both genotypes and phenotypes, for each of the 28 strains currently underway.

The company previously entered into a joint venture agreement with Supra Research and Development, creating Supra THC Services, a Health Canada licensed cannabis testing lab, and intends to be on the leading edge of scientific research and development of products and services related to the medical cannabis industry.

John Miller, President and CEO of THC BioMed, stated: "We now look forward to providing the highest quality products to our customers and bringing value to our shareholders as we work to build a world class Cannabis Company."

The shares are trading at $0.12 and with 95.7 million shares currently outstanding, the company is capitalized at $11.5 million.

For more information, please visit www.THCbiomed.com or www.supraTHC.com or contact John Miller, President & CEO, at 604-682-1643 or email info@THCbiomed.com.

About InvestmentPitch Media

InvestmentPitch Media is arguably the largest producer and distributer of video content, primarily for small and mid-cap companies. The company specializes in producing short videos based on significant news releases, research reports and other content of interest to investors.

CONTACT:
InvestmentPitch Media
Barry Morgan, CFO
bmorgan@investmentpitch.com